Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.
Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.
复制标题
开发用于前列腺癌免疫治疗的树突状细胞多核苷酸疫苗接种。
DOI：
10.1016/s0168-1656(99)00118-2
复制
发表时间：
1999
影响因子：
4.1
通讯作者：
Malone,RW
中科院分区：
文献类型：
--
作者：
Berlyn,KA;Ponniah,S;Stass,SA;Malone,JG;Hamlin-Green,G;Lim,JK;Cottler-Fox,M;Tricot,G;Alexander,RB;Mann,DL;Malone,RW
免疫疗法已成功地用于治疗一些人类恶性肿瘤，主要是黑色素瘤和肾细胞癌。提出了基于遗传的癌症免疫疗法，其引发T淋巴细胞识别由特定突变产生的独特新抗原。基因免疫（多核苷酸疫苗接种，DNA疫苗）是一个过程，其中基因治疗方法用于创建疫苗和免疫疗法。最近的研究表明，基因免疫间接地通过骨髓来源的细胞，可能是一种树突状抗原呈递细胞（APC）。直接靶向这些细胞的基因疫苗可能提供一种有效的方法，刺激细胞和体液免疫反应的感染因子和肿瘤抗原。最初的研究提供了单核细胞来源的树突状细胞（DC）的分离和培养技术，简单的方法，将基因导入这些细胞，也发现了潜在的障碍，有效的癌症免疫治疗可能会限制这种模式的效用，一个子集的患者。
Immunotherapy has been successfully used to treat some human malignancies, principally melanoma and renal cell carcinoma. Genetic-based cancer immunotherapies were proposed which prime T lymphocyte recognition of unique neo-antigens arising from specific mutations. Genetic immunization (polynucleotide vaccination, DNA vaccines) is a process whereby gene therapy methods are used to create vaccines and immunotherapies. Recent findings indicate that genetic immunization works indirectly via a bone marrow derived cell, probably a type of dendritic antigen presenting cell (APC). Direct targeting of genetic vaccines to these cells may provide an efficient method for stimulating cellular and humoral immune responses to infectious agents and tumor antigens. Initial studies have provided monocytic-derived dendritic cell (DC) isolation and culture techniques, simple methods for delivering genes into these cells, and have also uncovered potential obstacles to effective cancer immunotherapy which may restrict the utility of this paradigm to a subset of patients.